EGCG inhibits activation of the insulin-like growth factor (IGF)/IGF-1 receptor axis in human hepatocellular carcinoma cells.

Medicine and Dentistry

• Hepatocellular Carcinoma 100%
• Carcinoma Cell 100%
• Somatomedin C Receptor 100%
• Somatomedin 100%
• Cell Signaling Pathway 28%
• Somatomedin C 28%
• Hepatocyte 14%
• Programmed Cell Death 14%
• Cell Proliferation 14%
• Signaling Molecule 14%
• Protein Tyrosine Kinase 14%
• Chemoprophylaxis 14%
• Liver Cancer 14%
• Sphingolipid Activator Protein 2 14%
• Somatomedin B 14%
• Hepatocellular Carcinoma Cell Line 14%
• Protein Kinase B 14%
• Glycogen Synthase Kinase 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Liver Cell Carcinoma 100%
• Somatomedin C Receptor 100%
• Somatomedin 100%
• Somatomedin C 28%
• Normal Human 14%
• Glycogen Synthase Kinase 14%
• Protein Tyrosine Kinase 14%
• Liver Cancer 14%
• Somatomedin B 14%
• Sphingolipid Activator Protein 2 14%
• Protein Kinase B 14%

Biochemistry, Genetics and Molecular Biology

• Insulin-Like Growth Factor 100%
• Insulin-Like Growth Factor 1 Receptor 100%
• Insulin-Like Growth Factor 1 28%
• Hepatocyte 14%
• Normal Human 14%
• Cell Proliferation 14%
• GSK-3 14%
• Receptor Tyrosine Kinase 14%
• Protein Kinase B 14%
• Insulin-Like Growth Factor 2 14%
• Programmed Cell Death 14%